ESMO open
Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer.
J B Lee, K H Kim, S Yoon, S Y Song, S S Lee, S Jo, H K Ahn, H J Kim, S J Choi, H Park, M H Hong, B C Cho, H I Yoon, S M Lim
Published: 202610.1016/j.esmoop.2025.106057
Abstract
BACKGROUND: Lazertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that demonstrated progression-free survival (PFS) benefit in treatment-naive, EGFR-mutant advanced non-small-cell lung cancer (NSCLC)…
Preview only. Read the full abstract at the source